Lipoprotein(a): A Genetic Risk Factor for Premature Coronary Heart Disease

JAMA: The Journal of the American Medical Association

Volumn 267, Issue 24, 1992, Pages 3326-3329

  Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; GLYCOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLASMINOGEN;

ARTERY WALL; ATHEROSCLEROSIS; DIET THERAPY; EXERCISE; GENETIC RISK; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; RISK FACTOR; THROMBOSIS;

ANIMAL; CHOLESTEROL, DIETARY; CORONARY DISEASE; EXERCISE; HUMAN; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, LDL CHOLESTEROL; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 85047690177     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.267.24.3326     Document Type: Article

References (49)

1. Scanu AM, Fless GM. Lp(a): lipoprotein(a): heterogeneity and biological relevance. J Clin Invest. 1991;85:1709-1715.
2. Scanu AM. Lipoprotein(a): a genetically determined cardiovascular pathogen in search of a function. J Lab Clin Med. 1990;116:142-146.
3. Fless GM, Pfaffinger DJ, Eisenbart JD, Scanu AM. Solubility, immunochemical, and lipoprotein binding properties of apoB1OO-apo(a), the protein moiety of lipoprotein(a). J Lipid Res. 1990;31:909-918.
4. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
5. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
6. Makino K, Scanu AM. Lipoprotein(a): nonhuman primate models. Lipids. 1991;26:679-683.
7. Tomlinson JE, McLean JW, Lawn RM. Rhesus monkey apolipoprotein(a): sequence, evolution and site of synthesis. J Biol Chem. 1989;264:5957-5965.
8. Laplaud PM, Beaubatie L, Rall SJ Jr, Luc G, Saboureau M. Lipoprotein(a) is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog. J Lipid Res. 1988;29:1157-1170.
9. Lackner C, Boerwinkle E, Leffert C, Rahmig T, Hobbs H. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87:2153-2161.
10. Azrolan N, Gavish D, Breslow JL. Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo[a]) size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model. J Biol Chem. 1991;266:13866-13872.
11. Henriksson P, Angelin B, Berglund L. Hormonal effects on serum Lp(a) levels: marked reduction during estrogen treatment in males with prostatic cancer. Arterioscler Thromb. 1991;11: 1423a.
12. Albers JJ, Taggart H, Applebaum-Bowden D, Haffner S, Chesnut CH, Hazzard WR. Reduction of lecithin cholesterol acyl transferase, apolipoprotein B and Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta. 1984;795:293-296.
13. Kapelrud H, Bangstad H-J, Dahl-Jorgensen K, Berg K, Hanssen KF. Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:675-678.
14. Mbewu AD, Durrington PN. Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis. 1990;85:1-14.
15. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem. 1987;33:721-725.
16. Jenkins AJ, Steele JS, Janus ED, Best JD. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes. 1991;40: 787-790.
17. Edelstein C, Pfaffinger D, Scanu AM. Long term primary human hepatocytes in culture produce an apoB-apo(a) complex that is isolated from the medium at density <1.006 g/ml. Arterioscler Thromb. 1991;11:1424a.
18. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand. 1963;59: 369-382.
19. Scanu AM, Scandiani L. Lipoprotein(a): structure, biology and clinical relevance. Adv Intern Med. 1991:36;249-270.
20. Dahlen G. Incidence of Lp(a) among populations. In: Scanu AM, ed. Lipoprotein(a). Orlando, Fla: Academic Press Inc; 1990;11:151-173.
21. Sorrentino MJ, Vielhauer C, Eisenbart JD, Fless GM, Scanu AM, Feldman T. Plasma lipoprotein(a) protein concentration in coronary artery disease in black patients compared with white patients. Am J Med. In press.
22. Walton KW, Hitchens J, Magnani HN, Khan M. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis. 1974;20:323-346.
23. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantitation of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-592.
24. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989;9:593-603.
25. Niendorf A, Rath M, Wolf K, et al. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions. Virchows Arch A Pathol Anat Histopathol. 1990;417:105-111.
26. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein, II: preferential immobilization of lipoprotein (a) Lp(a). Atherosclerosis. 1990;84:173-181.
27. Pepin JM, O’Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res. 1991;32:317-327.
28. Loscalzo J. A unique risk factor for atherothrombotic disease. Arteriosclerosis. 1990;10:672-679.
29. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost. 1990; 63:331-335.
30. Scanu AM. Lipoprotein(a) as a cardiovascular risk factor. Trends Cardiovasc Med. 1991;1:294-299.
31. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
32. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
33. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of Lp(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 1992;267:4143-4151.
34. Naruszewicz M, Selinger E, Davignon J. Oxidation of Lp(a) particles increase their uptake by macrophages. Arteriosclerosis. 1990;10:808a.
35. Borth W, Chang V, Bishop P, Harpel PC. Lipoprotein(a) is a substrate for factor XIIIa and tissue transglutaminase. J Biol Chem. 1991;266: 18149-18153.
36. Scanu AM, Pfaffinger D, Fless GM, Makino K, Eisenbart J, Hinman J. Attenuation of immunological reactivity of lipoprotein(a) by thiols and cysteine-containing compounds: structural implications. Arterioscler Thromb. 1992;12:424-429.
37. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill International Book Co; 1989:693-734.
38. Seed D, Hoppichler F, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in FH. N Engl J Med. 1990;322:1494-1499.
39. Wiklund O, Angelin B, Olofsson SO, et al. Apolipoprotein(a) and ischemic heart disease in familial hypercholesterolemia. Lancet. 1990;335:1360-1363.
40. Mbewu AD, Bahatnagar PN, Durrington L, et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb. 1991;11:940-946.
41. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetyl cysteine. Lancet. 1991;337:203-204.
42. Schmidt EB, Klausen IC, Kristensen SD, Lervang HH, Faergeman O, Dyeberg J. The effect of n-3 polyunsaturated fatty acid on Lp(a). Clin Chim Acta. 1991;198:271-278.
43. Beil FU, Terres W, Orgass M, Greten H. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. Atherosclerosis. 1991;90:95-97.
44. Gurakar A, Hoeg JM, Kostner G, Papadopoulos M, Brewer HB Jr. Levels of lipoprotein(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.
45. Carlsson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemia subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
46. Jones PH, Gotto AM, Pownall HJ, et al. Effect of gemfibrozil on plasma lipoprotein(a) levels in type IIa hyperlipoproteinemic subjects. Arterioscler Thromb. 1991;11:1423a.
47. Levitsky LL, Scanu AM, Gould SH. Lipoprotein (a) levels in black and white children and adolescents with insulin dependent diabetes mellitus. Diabetes Care. 1991;14:283-287.
48. Haffner SM, Tuttle KR, Rainwater DL. Decrease of Lp(a) with improved glycemic control in subjects with insulin-dependent diabetes mellitus. Diabetes Care. 1991;14:302-307.
49. Armstrong VW, Schleef J, Thiery J, et al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest. 1989;19:235-240.